Matthew Robbins, MD, author of “COVID-19 and headache: a primer for trainees,” details how care has changed for patients with chronic headaches in the midst of the COVID-19 pandemic.
The researchers aimed to describe the prevalence of pre-cluster (premonitory) symptoms and examine the predictability of an upcoming cluster headache bout.
The Clinical Trials Subcommittee of the IHS penned this statement to facilitate the development of an evidence base for new medications and devices for migraine treatment.
The first Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention has been published in Cephalalgia by the Clinical Trials Subcommittee of the International Headache Society.
The investigators explored the relationships between headache frequency and characteristics, medication use, and quality of life in patients with chronic migraine and medication overuse headache.
The objective of this post hoc analysis is to better assess the benefits of fremanezumab in patients who responded to treatment during 2 phase 3 HALO clinical trials.
